Fundamentals of Transplant and Cellular Therapy- Day 2 - CAR-T - Enduring Material - Credit offering period June 16, 2026 - December 31, 2026
Kathleen Farringer, CRNP
* Scientific basis/Immuno-effector cells
References:
Michael D. Jain, Melody Smith, Nirali N. Shah; How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 2023; 141 (20): 2430-2442, doi: https://doi.org/10.1182/blood.2022017414
https://my.clevelandclinic.org/health/treatments/17726-car-t-cell-therapy
Target Audience
Physicians, nurses, pharmacists, and allied health care professionals who practice in hematological-medical units, skilled nursing facilities, home care, hospice, radiation oncology, surgical oncology, and/or cellular transplant.
Learning Objectives
Discuss mechanism of action
Review approved uses and treatments
Evaluate short- and long-term efficacy
Allegheny General Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Allegheny General Hospital designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
Available Credit
- 0.50 AMA PRA Category 1 Credit™

Facebook
X
LinkedIn
Forward